Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Doxorubicin-dextran conjugate

Danauser-Reidl S, Hausmann E, Schick H, Bender R, Dietzfelbinger H, Rastetter J, Hanauske A-R. Phase-I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest New Drugs 1993 11 187-195. [Pg.63]

Mitra S, Gaur U, Ghosh P C, et al. (2001). Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J. Control. Rel. 74 317-323. [Pg.153]

Conjugation of a 2-nitroimidazole derivative to carboxymethyl dextran allowed doxorubicin-loading with hypoxia-induced cellular uptake and cytotoxicity in vitro [110]. The dextran group for stability in the circulation and primary tumor accumulation was combined with conversion from a hydrophobic 2-nitroimidazole to a hydrophilic 2-aminoimidazole under hypoxia to promote doxorubicin release in tumor environment. This system showed a 4-fold doxorubicin accumulation in tumor over liver, lung, spleen, kidney, and heart 24 h after systemic injection and enhanced anticancer activity in vivo over free drug. [Pg.321]

See other pages where Doxorubicin-dextran conjugate is mentioned: [Pg.80]    [Pg.588]    [Pg.80]    [Pg.588]    [Pg.37]    [Pg.37]    [Pg.151]    [Pg.214]    [Pg.291]    [Pg.68]    [Pg.547]    [Pg.125]    [Pg.286]    [Pg.37]    [Pg.37]    [Pg.792]    [Pg.58]    [Pg.381]    [Pg.1460]   
See also in sourсe #XX -- [ Pg.80 ]



SEARCH



Dextran conjugates

Dextran-doxorubicin

Doxorubicin

Doxorubicin conjugate

Doxorubicine

© 2024 chempedia.info